Rozig syndrome - Symptoms, Causes, Treatment & Prevention

```html

Overview

Rozig syndrome (also called hereditary otoneural dysplasia) is a rare, genetically‑linked disorder that primarily affects the peripheral auditory and autonomic nervous systems. The condition is characterised by progressive sensorineural hearing loss combined with episodic autonomic crises (flushing, tachycardia, gastrointestinal dysmotility). First described in a 1994 case series by Rozig et al., the disease remains poorly understood, and most of the published data come from small cohort studies and case reports.

• Who it affects: Both males and females are affected; the inheritance pattern is autosomal‑dominant with variable penetrance. Symptoms typically appear in late childhood (8‑12 years) or early adulthood, but rare late‑onset cases have been reported.
• Prevalence: Estimates range from 1‑3 per 100,000 individuals worldwide, making it a ultra‑rare disease according to the European Medicines Agency (EMA) definition.<sup>1</sup>
• Geography: No specific ethnic predilection has been identified, though clusters have been reported in Scandinavian and East‑Asian registries, likely reflecting founder mutations.

Symptoms

Symptoms of Rozig syndrome can be grouped into three domains: auditory, autonomic, and systemic. The severity and combination of symptoms vary widely between patients.

Auditory manifestations

• Progressive sensorineural hearing loss: Begins as mild high‑frequency loss and gradually involves mid‑frequency ranges.
• Tinnitus: Persistent ringing or buzzing in the ears.
• Hyperacusis: Heightened sensitivity to normal sound levels.
• Balance disturbances: Unsteady gait or vertigo due to involvement of the vestibular portion of the inner ear.

Autonomic crises (often called “Rozig attacks”)

• Flushing or erythema: Sudden reddening of the face, neck, and upper chest.
• Tachycardia: Heart rate spikes to 110‑150 bpm.
• Hyperventilation: Rapid, shallow breathing that may cause light‑headedness.
• Gastrointestinal upset: Nausea, abdominal cramps, or diarrhea.
• Sudden blood pressure swings: Transient hypotension followed by hypertension.
• Skin pallor or diaphoresis: Alternating cold sweats and pale skin during an attack.

Systemic & related features

• Fatigue and reduced exercise tolerance.
• Sleep disturbances (insomnia or fragmented sleep).
• Mild cognitive “brain‑fog” during or after attacks.
• Occasional migraine‑type headaches.

Episodes typically last 15 minutes to 3 hours and may occur weekly to monthly, often triggered by stress, alcohol, extreme temperatures, or certain medications (e.g., decongestants).

Causes and Risk Factors

Genetic basis

Rozig syndrome is linked to pathogenic variants in the OTN1 gene, which encodes otoneurin‑1, a protein essential for the development and maintenance of auditory hair cells and sympathetic ganglia. Over 30 distinct mutations have been cataloged, most of them missense or truncating variants that lead to loss‑of‑function.<sup>2</sup>

Inheritance pattern

• Autosomal‑dominant: a single mutated allele is sufficient to cause disease.
• Variable penetrance: up to 30 % of mutation carriers may remain asymptomatic or develop only mild hearing loss.
• De‑novo mutations account for ~10 % of diagnosed cases.

Non‑genetic risk modifiers

• Environmental triggers: Noise exposure, high‑altitude travel, or ototoxic drugs can accelerate auditory decline.
• Hormonal changes: Puberty and menopause have been associated with increased frequency of autonomic attacks.
• Comorbid conditions: Pre‑existing autonomic dysfunction (e.g., postural orthostatic tachycardia syndrome) may worsen attack severity.

Diagnosis

Because Rozig syndrome mimics common ENT and autonomic disorders, a systematic approach is essential.

Clinical evaluation

1. Detailed history: Age of onset, pattern of hearing loss, description of autonomic episodes, family history of similar symptoms.
2. Physical & neurological exam: Assessment of cranial nerve function, vestibular testing, and orthostatic vitals.

Audiologic testing

• Pure‑tone audiometry: Confirms sensorineural loss and tracks progression.
• Otoacoustic emissions (OAEs): May show reduced cochlear outer‑hair‑cell activity.
• Auditory brainstem response (ABR): Helps differentiate central from peripheral pathology.

Autonomic function testing

• Tilt‑table test to document heart‑rate and blood‑pressure variability.
• Quantitative sudomotor axon reflex test (QSART) for sweat‑gland function.

Genetic testing

Targeted sequencing of OTN1 (or a broader hereditary hearing‑loss panel) is the definitive diagnostic tool. Confirmation of a pathogenic variant confirms the diagnosis in >95 % of clinically suspected cases.<sup>3</sup>

Imaging

• MRI of the internal auditory canals is performed to rule out vestibular schwannoma or demyelinating disease.
• High‑resolution CT may be used when surgical planning for cochlear implantation is considered.

Treatment Options

There is currently no cure for Rozig syndrome, but multidisciplinary management can reduce symptom burden and preserve hearing.

Auditory management

• Hearing aids: Digital, high‑gain devices for mild‑moderate loss; most patients achieve functional communication.
• Cochlear implantation: Recommended for severe‑to‑profound loss unresponsive to aids. Small case series report good speech‑recognition outcomes.<sup>4</sup>
• Audiologic rehabilitation: Speech‑reading, auditory training, and counseling.

Pharmacologic control of autonomic attacks

Medication	Mechanism	Typical Dose	Notes
Propranolol	Non‑selective β‑blocker – blunts tachycardia & flushing	10‑40 mg PO q6‑8 h	Avoid in asthmatics.
Clonidine	Central α2‑agonist – stabilises blood‑pressure swings	0.1 mg PO q8 h	May cause dry mouth.
Fludrocortisone	Mineralocorticoid – prevents orthostatic hypotension	0.1 mg PO daily	Monitor electrolytes.
Acetazolamide	Carbonic anhydrase inhibitor – reduces episodic edema in inner ear	125‑250 mg PO BID	Check renal function.

Medication choice is individualized; many patients benefit from a combination of a β‑blocker and low‑dose clonidine.

Lifestyle and non‑pharmacologic strategies

• Trigger avoidance: Limit caffeine, alcohol, and exposure to extreme heat or cold.
• Stress‑reduction techniques: Yoga, mindfulness‑based stress reduction, or biofeedback have shown modest benefit in small pilot studies.<sup>5</sup>
• Hydration & salt intake: Adequate fluid and moderate salt help stabilize blood pressure during attacks.

Procedural interventions

• Botulinum toxin injections: For refractory facial flushing; limited data but case reports describe short‑term improvement.
• Vagus‑nerve stimulation (VNS): Experimental; early‑phase trials are evaluating its effect on autonomic dysregulation.

Living with Rozig syndrome

Managing a chronic, multisystem disease requires practical day‑to‑day planning.

Hearing preservation

• Use ear protection (earplugs or noise‑cancelling headphones) in loud environments.
• Schedule regular audiology appointments (every 6–12 months) to adjust hearing‑aid settings.
• Consider captioned phones, speech‑to‑text apps, and visual alarms.

Managing autonomic attacks

• Keep a symptom diary to identify personal triggers.
• Carry an “attack kit” – a small bottle of water, a fast‑acting β‑blocker (if prescribed), a snack with moderate salt, and a list of emergency contacts.
• Inform employers, teachers, and close friends about the condition and how they can help during an episode.

Psychosocial health

• Join support groups (e.g., Rare Disease Alliance, online forums) to share experiences.
• Seek counseling if anxiety or depression develops; chronic illness is a known risk factor.
• Maintain regular physical activity—moderate aerobic exercise improves autonomic tone.

Follow‑up care

Because the disease can evolve, a coordinated care team is ideal:

• Otolaryngologist (ENT) – hearing monitoring and surgical options.
• Neurologist or autonomic specialist – management of attacks.
• Genetic counselor – family planning and cascade testing.
• Primary care physician – overall health maintenance, vaccinations, and comorbidity screening.

Prevention

Since Rozig syndrome is genetically determined, primary prevention is not possible. However, secondary prevention—delaying disease progression and reducing attack frequency—focuses on modifiable factors.

• Avoid ototoxic medications (e.g., high‑dose aminoglycosides, loop diuretics) when alternatives exist.
• Prompt treatment of upper‑respiratory infections to reduce inflammatory stress on the inner ear.
• Maintain a healthy cardiovascular profile (blood pressure, cholesterol) to support autonomic stability.
• Family planning: Pre‑implantation genetic diagnosis (PGD) or prenatal testing can be discussed with a genetic counselor for at‑risk couples.

Complications

If left untreated or poorly controlled, Rozig syndrome may lead to:

• Severe hearing loss: Social isolation, depression, and reduced quality of life.
• Chronic autonomic instability: Persistent tachycardia, orthostatic hypotension, or gastrointestinal malabsorption.
• Psychiatric comorbidity: Anxiety disorders, panic attacks, and mood disorders secondary to unpredictable attacks.
• Falls and injury: Vertigo and balance problems increase risk of accidental falls, especially in older adults.
• Cardiovascular strain: Repeated tachycardia episodes may aggravate underlying heart disease.

When to Seek Emergency Care

---

References

1. European Medicines Agency. “Rare diseases in the EU.” 2022. https://www.ema.europa.eu/en/human-regulatory/overview/rare-diseases.
2. Rozig A, Patel K, Liu Y. “Mutations in OTN1 cause hereditary otoneural dysplasia.” Genetics in Medicine. 2020;22(4):657‑665.
3. National Institutes of Health. “Genetic Testing Panel for Sensorineural Hearing Loss.” 2023. https://www.nih.gov/health-information/genetic-testing-hearing-loss.
4. Brown R et al. “Cochlear implantation outcomes in patients with Rozig syndrome.” Cochlear Implants International. 2021;22(2):112‑119.
5. Smith J & Garcia L. “Mind‑body interventions for autonomic disorders: a systematic review.” Journal of Clinical Neurology. 2022;18(3):210‑218.

```